PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRilpivirine
Edurant, Eviplera(rilpivirine)
Cabenuva, Complera, Edurant, Eviplera, Juluca, Odefsey, Rekambys (rilpivirine) is a small molecule pharmaceutical. Rilpivirine was first approved as Edurant on 2011-05-20. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
FDA Novel Drug Approvals 2021
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Edurant (discontinued: Edurant ped)
Combinations
Cabenuva, Complera, Juluca, Odefsey
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rilpivirine hydrochloride
Tradename
Company
Number
Date
Products
EDURANTJohnson & JohnsonN-202022 RX2011-05-20
1 products, RLD, RS
Show 1 discontinued
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
COMPLERAGilead SciencesN-202123 RX2011-08-10
1 products, RLD, RS
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
ODEFSEYGilead SciencesN-208351 RX2016-03-01
1 products, RLD, RS
Cabotegravir
+
Rilpivirine
Tradename
Company
Number
Date
Products
CABENUVA KITViiV HealthcareN-212888 RX2021-01-21
2 products, RLD, RS
Dolutegravir sodium
+
Rilpivirine hydrochloride
Tradename
Company
Number
Date
Products
JULUCAViiV HealthcareN-210192 RX2017-11-21
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cabenuvaNew Drug Application2024-09-20
compleraNew Drug Application2024-09-24
complera accessExport only2024-09-23
edurantNew Drug Application2022-11-02
edurant edurant pedNew Drug Application2025-02-07
julucaNew Drug Application2024-04-18
odefseyNew Drug Application2025-02-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
hiv—D006678O98.7
chronic hepatitis bEFO_0004239D019694B18.1
Agency Specific
FDA
EMA
Expiration
Code
CABOTEGRAVIR / RILPIVIRINE, CABENUVA KIT, VIIV HLTHCARE
2026-01-21NCE
2025-03-29NPP
2025-01-31D-184
Patent Expiration
Patent
Expires
Flag
FDA Information
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc
108571022033-01-14DP
88413102025-12-09DPU-257
85923972024-01-13DPU-257
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Alafenamide Fumarate, Odefsey, Gilead Sciences Inc
87540652032-08-15DS, DPU-257
92967692032-08-15DS, DPU-257
73907912025-04-17DS, DP
Cabotegravir / Rilpivirine, Cabenuva Kit, Viiv Hlthcare
112245972031-09-15DPU-3348
113894472027-06-30U-3405
84101032026-04-28DS, DPU-3348
109271292026-04-28DS, DP
71258792025-04-21DS, DPU-257, U-1153, U-1307, U-1740, U-3348, U-3353
Dolutegravir Sodium / Rilpivirine Hydrochloride, Juluca, Viiv Hlthcare
104267802031-01-24DS, DPU-257
92429862029-12-08DS, DP
81293852027-10-05DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AG: Non-nucleoside reverse transcriptase inhibitors
— J05AG05: Rilpivirine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR08: Emtricitabine, tenofovir disoproxil and rilpivirine
— J05AR19: Emtricitabine, tenofovir alafenamide and rilpivirine
— J05AR21: Dolutegravir and rilpivirine
HCPCS
Code
Description
J0741
Injection, cabotegravir and rilpivirine, 2mg/3mg
Clinical
Clinical Trials
173 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv seropositivityD006679—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B203312——17
Acquired immunodeficiency syndromeD000163EFO_0000765B20124——7
Immunologic deficiency syndromesD007153—D84.9—23——5
InfectionsD007239EFO_0000544—112——4
Communicable diseasesD003141———12——3
HivD006678—O98.7—11—13
Hiv-1D015497———21——3
Hepatitis cD006526—B19.2——1——1
Chronic hepatitis cD019698EFO_0004220B18.2——1——1
HepatitisD006505—K75.9——1——1
Show 2 more
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRilpivirine
INNrilpivirine
Description
Rilpivirine is an aminopyrimidine that is pyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 4-cyanophenyl and 4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl groups respectively. Used for treatment of HIV. It has a role as a HIV-1 reverse transcriptase inhibitor and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a nitrile and an aminopyrimidine. It is a conjugate base of a rilpivirine(1+).
Classification
Small molecule
Drug classantivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1
Identifiers
PDB—
CAS-ID500287-72-9
RxCUI—
ChEMBL IDCHEMBL175691
ChEBI ID68606
PubChem CID6451164
DrugBankDB08864
UNII IDFI96A8X663 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Complera – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Odefsey – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Edurant – Johnson & Johnson
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rilpivirine
+
Emtricitabine
+
Tenofovir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,596 documents
View more details
Safety
Black-box Warning
Black-box warning for: Complera, Complera access, Odefsey
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18,034 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use